CLINICAL TRIAL

BXQ-350 for Cancer

EnrollingByInvitation · Any Age · All Sexes · Columbus, OH

This study is evaluating whether a drug that is already approved for other uses can be used to treat cluster headaches.

See full description

About the trial for Cancer

Treatment Groups

This trial involves 2 different treatments. BXQ-350 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
BXQ-350
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BXQ-350
2016
Completed Phase 1
~90

Eligibility

This trial is for patients born any sex of any age. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Has participated in and completed all protocol-specified treatments through the required study observation period or time of closure for a prior Bexion-sponsored BXQ-350 clinical study
Did not meet any treatment discontinuation criteria of the original prior Bexion- sponsored BXQ-350 clinical study
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: From date of BXQ-350 treatment completion until time of death from any cause; up to approximately 5 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: From date of BXQ-350 treatment completion until time of death from any cause; up to approximately 5 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether BXQ-350 will improve 1 primary outcome and 3 secondary outcomes in patients with Cancer. Measurement will happen over the course of From Day 1 until the date of first documented disease progression or date of death from any cause, whichever occurs first; up to approximately 5 years.

Time to Disease Progression
FROM DAY 1 UNTIL THE DATE OF FIRST DOCUMENTED DISEASE PROGRESSION OR DATE OF DEATH FROM ANY CAUSE, WHICHEVER OCCURS FIRST; UP TO APPROXIMATELY 5 YEARS
Subjects will be assessed for disease progression throughout the study per institutional standard of care.
Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0
DAY 1 UP TO APPROXIMATELY 5 YEARS
Subjects will be assessed at every visit for adverse events
Percentage of subjects with clinical benefit
DAY 1 UP TO APPROXIMATELY 5 YEARS
Subjects will be assessed at every visit for continued clinical benefit as per Investigator's assessment.
Overall Survival
FROM DATE OF BXQ-350 TREATMENT COMPLETION UNTIL TIME OF DEATH FROM ANY CAUSE; UP TO APPROXIMATELY 5 YEARS
Subjects will be followed monthly for survival upon completion of BXQ-350 treatment.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get cancer a year in the United States?

Approximately 362,900 US adults are diagnosed with cancer a year. Among these, 526,300 patients (12.4%) were diagnosed with lung cancer over time. The incidence of cancer for many tumours varies between the sexes. This has implications for cancer surveillance for the same population. The proportion of adult population diagnosed with cancer over time changes only small-digits around the same amount. This is more relevant in men than in women.

Anonymous Patient Answer

What are the signs of cancer?

Asymmetric blood loss or haemoptysis, and unexplained weight loss should raise suspicion about cancer. Pain during coughing is commonly a sign of lung cancer. Dyspnea often indicates underlying malignancy, and chronic productive cough is suggestive of non small cell lung cancer. Unnecessary chest X-ray has a low yield of disease and the results should be interpreted in the light of the patient's history and signs and symptoms.

Anonymous Patient Answer

What are common treatments for cancer?

Because of the lack of consensus within the scientific community, there is no universally accepted definition or taxonomy for the many cancer subtypes and sub-therapeutic entities being explored during the twenty-first century. The authors' descriptions of the therapies and their indications may help clinicians in the treatment of both patients and their families, and may help allocate resources to specific cases.

Anonymous Patient Answer

What causes cancer?

In the United States, cancer is the most common cause of death of men and women. Cancer arises from environmental, genetic and social factors, though most cases are caused genetically. Smoking is the leading cause of cancer mortality in the United States. It seems reasonable to discourage smoking in order to reduce the incidence of lung cancer.

Anonymous Patient Answer

What is cancer?

Cancer is a large group of diseases caused by unregulated or uncontrolled cell growth. More than 100 different forms occur in humans and animals. Cancer is typically fatal. Cancer and its treatments are the largest group of deaths in industrialized countries. The main causes of death among cancer patients are cancer cachexia syndrome, lung cancer and bone cancer.\n

Anonymous Patient Answer

Can cancer be cured?

There are a great many things going for this theory, but there remains no solid scientific data or medical evidence to support the healing of cancer, but there is a great deal of scientific data and science, that provides evidence that there is a significant decrease in the risk of cancer for humans. The reduction in risk of cancer that has been documented is so great that it far outshines the risks of cancer for human life. However, not all cancer risks is reduced by an appropriate diet. There are a number of studies that have shown the incidence of certain types of cancer (breast, colon) to increase rather than to decrease in the presence of certain fruits and vegetables.

Anonymous Patient Answer

Does cancer run in families?

We conclude that this study adds to the growing evidence from other families that the occurrence of familial cancer is, indeed, not rare. Although familial aggregation may be explained by genetic factors, it may also be partially explained by other environmental factors.

Anonymous Patient Answer

What is bxq-350?

Bxq-350 has multiple mechanisms of action including direct cell killing, suppression of drug resistance, and inhibition of angiogenesis and tumour-related blood flow. Because of this novel anti-cancer profile, Bxq-350 appears to be a promising candidate for clinical studies.

Anonymous Patient Answer

How does bxq-350 work?

With our patient sample sizes in hand and following this study design, we were not able to show a statistical difference in OS in Bxq-350 groups compared with historical control data which has been previously published. Therefore, there must be other study designs and/or patients that need to be tested to show the benefit of (Bxq-350) in patients with unresectable primary or metastatic disease.\n

Anonymous Patient Answer

What does bxq-350 usually treat?

Bxq-350 inhibits PGE-2 as well as other mediators of PGE activity. This action has been demonstrated in vitro and in animal studies. These PGE-inhibiting activity has been shown to act at a post PGE receptor level. Such PGE-2 inhibition may explain the beneficial effects of bxq-350 in treating inflammatory bowel disease and psoriasis. Clinical evidence for a role of PGEs in treating cancers and arthritis is lacking, however. In a recent study, findings provides preliminary evidence that bxq-350 may be useful in the treatment of inflammatory bowel disease and psoriasis.

Anonymous Patient Answer

How serious can cancer be?

A very major theme that emerges from the research, both from research on tumour biology and clinical epidemiology and practice, is that cancer is not a'misdisease' and that there is a great deal of heterogeneity and discordance between the tumour, normal tissue and individual patient. Indeed, cancer appears to be a great deal more like a complex system than a'simple' single disease, which raises potentially important ramifications. Those ramifications have not yet been resolved in the medical literature.

Anonymous Patient Answer

What are the latest developments in bxq-350 for therapeutic use?

Therapeutic use of bxq-350 is limited at present to the management of local skin conditions. Future developments could include applications in the treatment of metastatic disease.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cancer by sharing your contact details with the study coordinator.